111 related articles for article (PubMed ID: 16884757)
21. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Van Rompay KK; Trott KA; Jayashankar K; Geng Y; LaBranche CC; Johnson JA; Landucci G; Lipscomb J; Tarara RP; Canfield DR; Heneine W; Forthal DN; Montefiori D; Abel K
Retrovirology; 2012 Jul; 9():57. PubMed ID: 22805180
[TBL] [Abstract][Full Text] [Related]
22. An anti-HIV strategy combining chemotherapy and therapeutic vaccination.
Rosenwirth B; Bogers WM; Nieuwenhuis IG; Haaft PT; Niphuis H; Kuhn EM; Bischofberger N; Erfle V; Sutter G; Berglund P; Liljestrom P; Uberla K; Heeney JL
J Med Primatol; 1999; 28(4-5):195-205. PubMed ID: 10593486
[TBL] [Abstract][Full Text] [Related]
23. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
Tarantal AF; Marthas ML; Shaw JP; Cundy K; Bischofberger N
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):323-33. PubMed ID: 10096575
[TBL] [Abstract][Full Text] [Related]
24. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Van Rompay KK; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N
J Virol; 2004 May; 78(10):5324-37. PubMed ID: 15113912
[TBL] [Abstract][Full Text] [Related]
25. SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
Carruth LM; Zink MC; Tarwater PM; Miller MD; Li M; Queen LA; Mankowski JL; Shen A; Siliciano RF; Clements JE
J Med Primatol; 2005 Jun; 34(3):109-21. PubMed ID: 15860119
[TBL] [Abstract][Full Text] [Related]
26. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Van Rompay KK; Singh RP; Brignolo LL; Lawson JR; Schmidt KA; Pahar B; Canfield DR; Tarara RP; Sodora DL; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):900-14. PubMed ID: 15220696
[TBL] [Abstract][Full Text] [Related]
27. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Kubo M; Nishimura Y; Shingai M; Lee W; Brenchley J; Lafont B; Buckler-White A; Igarashi T; Martin MA
J Virol; 2009 Jul; 83(14):7099-108. PubMed ID: 19420078
[TBL] [Abstract][Full Text] [Related]
28. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.
Balzarini J; Naesens L; Slachmuylders J; Niphuis H; Rosenberg I; Holý A; Schellekens H; De Clercq E
AIDS; 1991 Jan; 5(1):21-8. PubMed ID: 2059358
[TBL] [Abstract][Full Text] [Related]
29. Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques.
Joag SV; Li Z; Foresman L; Pinson DM; Stephens EB; Raghavan R; Navé JF; Casara P; Narayan O
AIDS Res Hum Retroviruses; 1997 Feb; 13(3):241-6. PubMed ID: 9115811
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Shen Y; Shen L; Sehgal P; Zhou D; Simon M; Miller M; Enimi EA; Henckler B; Chalifoux L; Sehgal N; Gastron M; Letvin NL; Chen ZW
J Virol; 2001 Sep; 75(18):8690-6. PubMed ID: 11507214
[TBL] [Abstract][Full Text] [Related]
31. PMPA beats SIV again.
GMHC Treat Issues; 1996 May; 10(5):8-9. PubMed ID: 11363586
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Tsai CC; Emau P; Follis KE; Beck TW; Benveniste RE; Bischofberger N; Lifson JD; Morton WR
J Virol; 1998 May; 72(5):4265-73. PubMed ID: 9557716
[TBL] [Abstract][Full Text] [Related]
33. Control of SIV rebound through structured treatment interruptions during early infection.
Lori F; Lewis MG; Xu J; Varga G; Zinn DE; Crabbs C; Wagner W; Greenhouse J; Silvera P; Yalley-Ogunro J; Tinelli C; Lisziewicz J
Science; 2000 Nov; 290(5496):1591-3. PubMed ID: 11090360
[TBL] [Abstract][Full Text] [Related]
34. Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
Shen L; Shen Y; Huang D; Qiu L; Sehgal P; Du GZ; Miller MD; Letvin NL; Chen ZW
J Infect Dis; 2004 Oct; 190(8):1438-47. PubMed ID: 15378436
[TBL] [Abstract][Full Text] [Related]
35. Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Smith MS; Foresman L; Lopez GJ; Tsay J; Wodarz D; Lifson JD; Page A; Wang C; Li Z; Adany I; Buch S; Bischofberger N; Narayan O
Virology; 2000 Nov; 277(2):306-15. PubMed ID: 11080478
[TBL] [Abstract][Full Text] [Related]
36. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
Lifson JD; Rossio JL; Piatak M; Parks T; Li L; Kiser R; Coalter V; Fisher B; Flynn BM; Czajak S; Hirsch VM; Reimann KA; Schmitz JE; Ghrayeb J; Bischofberger N; Nowak MA; Desrosiers RC; Wodarz D
J Virol; 2001 Nov; 75(21):10187-99. PubMed ID: 11581387
[TBL] [Abstract][Full Text] [Related]
37. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
38. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
Lewis MG; Norelli S; Collins M; Barreca ML; Iraci N; Chirullo B; Yalley-Ogunro J; Greenhouse J; Titti F; Garaci E; Savarino A
Retrovirology; 2010 Mar; 7():21. PubMed ID: 20233398
[TBL] [Abstract][Full Text] [Related]
39. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.
George MD; Reay E; Sankaran S; Dandekar S
J Virol; 2005 Mar; 79(5):2709-19. PubMed ID: 15708990
[TBL] [Abstract][Full Text] [Related]
40. PMPA--first human results.
James JS
AIDS Treat News; 1997 Apr; (No 269):3, 6. PubMed ID: 11364254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
